Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.40 |
| ▸ | EGFR | P00533 | 3/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | HTR3A | P46098 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27868791 | 1.00 | KCNH2 (0.43) | KCNH2PFKFB3HRH4EGFRKDR | |
| SCHEMBL780503 | 0.82 | PFKFB3 (0.43) | PFKFB3HRH4JAK2JAK3NPC1 | |
| Hydrochloric Acid SCHEMBL16161587 | 0.82 | PFKFB3 (0.42) | PFKFB3HRH4JAK2JAK3 | |
| SCHEMBL13050390 | 0.80 | JAK3 (0.36) | PFKFB3HRH4HTR3AJAK2JAK3 | |
| SCHEMBL780421 | 0.79 | NUDT1 (0.47) | PFKFB3EGFRMEN1KMT2AHTT | |
| SCHEMBL27851794 | 0.79 | NUDT1 (0.47) | PFKFB3EGFRMEN1KMT2AHTT | |
| SCHEMBL18171887 | 0.79 | NUDT1 (0.47) | PFKFB3EGFRMEN1KMT2AHTT | |
| SCHEMBL782040 | 0.79 | HRH4 (0.46) | KCNH2HRH4JAK2 | |
| SCHEMBL782196 | 0.79 | PFKFB3 (0.41) | PFKFB3MEN1KMT2ANPC1KDM4E | |
| SCHEMBL780985 | 0.79 | TNF (0.42) | PFKFB3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435423-B1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P70S6 KINASE | SENTINEL ONCOLOGY LTD (GB) | 2014-10-15 | — | — | EP | disclosed |
| EP-2435423-B1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P70S6 KINASE | SENTINEL ONCOLOGY LTD (GB) | 2014-10-15 | — | — | EP | disclosed |
| US-8716473-B2 | Substituted benzotriazines and quinoxalines as inhibitors of P7OS6 kinase | SENTINEL ONCOLOGY LIMITED (GB) | 2014-05-06 | — | — | US | disclosed |
| US-8716473-B2 | Substituted benzotriazines and quinoxalines as inhibitors of P7OS6 kinase | SENTINEL ONCOLOGY LIMITED (GB) | 2014-05-06 | — | — | US | disclosed |
| CN-102459234-A | Substituted benzotriazines and quinoxalines as P70S6 kinase inhibitors | SENTINEL ONCOLOGY LTD | 2012-05-16 | — | — | CN | disclosed |
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2012-03-22 | — | — | US | disclosed |
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2012-03-22 | — | — | US | disclosed |
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2012-03-22 | — | — | US | disclosed |
| WO-2010136755-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | CDK1, CDK2, CDK6 | KCNH2 1428/4885PFKFB3 479/4885HRH4 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.